TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07771140: A Randomized, Double-blind, Placebo-controlled, Dose-escalating Phase I Trial With Single and Multiple Dosing to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of HECN30227 Injection in Healt

Sponsor: Sunshine Lake Pharma Co., Ltd. · Phase: PHASE1 · Area: INFECTIOUS_VACCINE · Target Enrollment: 78 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,397,440

Rescue Site Savings

+$4,218,312

Unlock Full NCT07771140 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07771140 Rescue Dossier →